Precision Multichannel tDCS for Depression: From Home-based Feasibility to Randomized Controlled Evidence

A new randomized sham-controlled trial suggests that computationally optimized multichannel tDCS may produce earlier and larger antidepressant effects than conventional bipolar stimulation. Viewed together with Neuroelectrics’ earlier home-based pilot, the field is starting to see a consistent signal: electric-field optimization and multielectrode delivery may matter.

A Stronger Signal for Precision Neuromodulation

The new Molecular Psychiatry trial by Salehinejad and colleagues compared three arms in major depressive disorder: optimized multichannel 4 mA tDCS, conventional 2 mA bipolar tDCS, and sham. The optimized protocol used seven small electrodes and a computational targeting strategy designed to better match the intended pattern of left prefrontal excitation and right prefrontal inhibition than a standard two-electrode montage can achieve. In the randomized trial, the optimized multichannel arm showed earlier and larger symptom reduction than conventional tDCS, with a mean MADRS change of 21.5 points at endpoint and a 75% response rate, versus 13.5 points and 45% for conventional tDCS, and 6.3 points and 20% for sham. Salehinejad et al., 2026

That result is notable on its own, but it becomes more compelling when linked to an earlier Neuroelectrics-led study published in 2024. In that open-label multicenter pilot, remotely supervised multichannel tDCS was delivered entirely at home to patients with major depressive disorder using a group-optimized montage targeting the left DLPFC. Patients completed 37 sessions over 8 weeks, and the study reported a mean MADRS improvement of 19.8 points at the 4-week post-treatment endpoint, a median MADRS reduction of 64.5%, and a 72.7% response rate. Ruffini et al., 2024

The translational message is straightforward: the 2024 pilot showed that multichannel, model-informed stimulation could be delivered safely and feasibly at home, while the 2026 randomized study suggests that a closely related multichannel strategy can also outperform sham under controlled conditions.

What Links The Two Multichannel tDCS Studies?

These are not identical protocols, and they should not be presented as if they were. The earlier study was open-label and home-based, whereas the newer trial was randomized and sham-controlled in a clinic-based research setting. Still, the overlap is meaningful. Both studies used multielectrode tDCS, both relied on electric-field modeling to improve targeting, both focused on prefrontal circuitry relevant to depression, and both delivered repeated treatment courses with roughly similar cumulative exposure. Most importantly, both observed antidepressant effects in the same range.

This is exactly the type of progression the field needs: a feasibility signal first, then a controlled efficacy signal. The 2024 pilot did not establish efficacy on its own, because it lacked sham control and blinding. But it did show that a home-based multichannel workflow was workable, safe, and associated with a large reduction in depressive symptoms. The 2026 trial then adds the missing ingredient by showing that an optimized multichannel configuration can separate from sham and do so more clearly than conventional bipolar tDCS. Ruffini et al., 2024; Salehinejad et al., 2026

Multichannel tDCS in Depression: Side-by-side Comparison

Feature	Home-based pilot	Randomized sham-controlled trial
Study	Ruffini et al., 2024	Salehinejad et al., 2026
Design	Open-label, multicenter pilot	Randomized, sham-controlled, three-arm trial
Setting	Tele-supervised, fully at home	Controlled clinical/research setting
Participants	34 in ITT / 35 enrolled with major depressive disorder	71 randomized, 60 with endpoint data
Stimulation approach	Multichannel tDCS with group-optimized electric-field targeting of left DLPFC	Computationally optimized 7-electrode multichannel 4 mA tDCS versus conventional 2 mA bipolar tDCS and sham
Sessions	37 sessions over 8 weeks: 4 weeks acute daily treatment plus 4 weeks taper	30 sessions with assessments during treatment and at 1- and 3-month follow-up
Primary clinical readout	MADRS change through 4-week post-treatment follow-up	MADRS change through week 6 endpoint
MADRS improvement	Mean change: 19.8 points; median reduction: 64.5%	Mean change: 21.5 points in optimized multichannel arm; 13.5 in conventional; 6.3 in sham
Response rate	72.7% at last visit	75% optimized multichannel; 45% conventional; 20% sham
Safety	No serious adverse events; adverse events were mild	No serious adverse events; higher stimulation-related sensations in optimized multichannel arm
Main limitation	No sham control and no blinding	Blinding unsuccessful in the optimized multichannel arm
Take-home message	Home-based multichannel targeting appears feasible and promising	Optimized multichannel stimulation shows controlled evidence of stronger antidepressant effects than sham, and larger effects than conventional bipolar tDCS

The comparison is intended to highlight continuity in direction, not to imply that the two protocols are interchangeable.

Summary figure illustrating the links between the 2024 tele-supervised home-based pilot and the 2026 randomized sham-controlled study, both of which reported large MADRS reductions with multielectrode targeted tDCS.

Why Precision Multichannel tDCS Matters for the Future of Depression Treatment

For years, one of the central questions in non-invasive brain stimulation has been whether better targeting can translate into better outcomes. These two studies suggest that it can.

The earlier Neuroelectrics-led pilot pointed to a practical deployment model: repeated, tele-supervised treatment delivered at home using multichannel stimulation and computational optimization. The newer controlled trial strengthens the scientific case by showing that a multichannel strategy can outperform sham and appear more effective than conventional bipolar stimulation. Ruffini et al., 2024; Salehinejad et al., 2026

The broader implication is not just that “more electrodes” are better. The real point is precision: using models to shape the electric field so that stimulation better aligns with the targeted network. That is a different proposition from simply increasing current or repeating the standard montage. It moves the field toward a more engineered and testable form of neuromodulation.

At the same time, caution remains necessary. The home-based study was open-label, so its efficacy signal must be interpreted conservatively. And in the randomized 2026 trial, blinding did not hold in the optimized arm, which means expectancy effects cannot be fully excluded. These are not small details. They define the next step for the field: larger confirmatory trials with improved sham design, richer biomarkers, and careful integration of comfort, usability, and precision targeting.

Key Takeaways: Precision Multichannel tDCS Shows Scalable and Clinically Meaningful Potential

Read together, the two studies support a coherent narrative. First, multichannel model-informed tDCS can be deployed safely and feasibly at home in depression, with encouraging symptom reductions. Second, a related optimized multichannel approach can also produce stronger outcomes than sham in a randomized controlled setting. That is not yet the end of the story, but it is a meaningful step toward precision neuromodulation that is both scalable and clinically relevant.

Both studies were conducted using Starstim, underscoring its ability to consistently deliver reproducible, multichannel, and computationally optimized stimulation across both real-world and controlled clinical settings.

References

1. Salehinejad MA, et al. Optimized multichannel 4 mA vs conventional transcranial direct current stimulation for major depressive disorder: A randomized sham-controlled trial. Molecular Psychiatry. 2026. https://www.nature.com/articles/s41380-026-03560-0

2. Ruffini G, et al. Multichannel tDCS with advanced targeting for major depressive disorder: a tele-supervised at-home pilot study. Frontiers in Psychiatry. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11358063/